🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

An International Challenge

The sexually transmitted infection are increasing around the world, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are reported in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Public health authorities are deeply concerned about the surge in treatment-resistant strains. The WHO has listed it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is also used to treat UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This approval marks a huge turning point in the management of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Global Access

As per results published in a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This puts it on an comparable level with the typical regimen, which uses two antibiotics. The trial involved hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Clinicians on the front lines have voiced positive views. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.